The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer.
A. Forero-Torres
Research Funding - Daiichi Sankyo; Susan G. Komen for the Cure
N. U. Lin
No relevant relationships to disclose
M. C. Liu
No relevant relationships to disclose
H. S. Rugo
No relevant relationships to disclose
S. Puhalla
No relevant relationships to disclose
R. Nanda
No relevant relationships to disclose
I. A. Mayer
No relevant relationships to disclose
A. M. Storniolo
No relevant relationships to disclose
T. A. Traina
No relevant relationships to disclose
D. F. Hayes
No relevant relationships to disclose
M. F. Rimawi
No relevant relationships to disclose
M. P. Goetz
No relevant relationships to disclose
F. J. Esteva
No relevant relationships to disclose
W. J. Irvin
No relevant relationships to disclose
A. C. Wolff
No relevant relationships to disclose